Diabetes drug semaglutide studied for lung clot recovery

NCT ID NCT06118203

Completed Knowledge-focused Sponsor: Imperial College London Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study tested whether semaglutide, a drug used for diabetes, could reduce inflammation in 18 people who had a blood clot in their lungs (pulmonary embolism). Researchers measured changes in blood markers of inflammation over 4 weeks. The goal was to see if the drug might help recovery, but the study was small and focused on lab results, not patient symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Semaglutide
What this could lead to: If this works, it could point toward a new way to reduce inflammation after a pulmonary embolism.
What could go wrong: This is a very small, early study that only measured blood markers, not patient outcomes. The results may not lead to any treatment change.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY EMBOLISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary embolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY EMBOLISM

Contacts and locations

Locations

Colm McCabe

London, SW3 6NP, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.